$CBIH
Cannabis Bioscience International Holdings, Inc. Stock $cbih

$cbih Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000168316824007261 Filed on October 21, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$178.9K	$72.82K
YoY Change		145.65%
Cost Of Revenue		$8.362K	$8.820K
YoY Change		-5.19%
Gross Profit		$170.5K	$64.00K
YoY Change		166.44%
Gross Profit Margin		95.33%	87.89%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$268.1K	$240.8K
YoY Change		11.36%
Operating Profit		-$97.60K	-$176.8K
YoY Change		-44.79%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$21.30K	-$5.005K
YoY Change		-525.55%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings		-$76.31K	-$181.8K
YoY Change		-58.03%	-14.26%
Net Earnings / Revenue		-42.66%	-249.64%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share		$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	10.56B shares	10.43B shares	10.33B shares
Diluted Shares Outstanding		10.46B shares	10.33B shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$969.00	$4.746K
Short-Term Investments
Other Short-Term Assets	$598.00
YoY Change
Inventory
Prepaid Expenses
Receivables	$17.18K
Other Receivables
Total Short-Term Assets	$18.74K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$27.54K
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$18.74K
Total Long-Term Assets	$27.54K
Total Assets	$46.28K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due	$7.054K
YoY Change
Total Short-Term Liabilities	$852.1K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$249.5K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$249.5K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$852.1K
Total Long-Term Liabilities	$249.5K
Total Liabilities	$1.102M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$5.410M
YoY Change
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.055M	-$717.5K
YoY Change
Total Liabilities & Shareholders Equity	$46.28K
YoY Change

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$76.31K	-$181.8K
YoY Change	-58.03%	-14.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$30.41K	-$74.62K
YoY Change	-59.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$30.63K	$70.45K
YoY Change	-56.53%
NET CHANGE
Cash From Operating Activities	-$30.41K	-$74.62K
Cash From Investing Activities
Cash From Financing Activities	$30.63K	$70.45K
Net Change In Cash	$214.00	-$4.167K
YoY Change	-105.14%
FREE CASH FLOW
Cash From Operating Activities	-$30.41K	-$74.62K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001411057
CY2024Q3	dei	City Area Code CityAreaCode	214
CY2024Q3	dei	Local Phone Number LocalPhoneNumber	733-0868
CY2024Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2024Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q3	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q3	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10556749347	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	969	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	755	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17176	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20139	usd
CY2024Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2024Q3	dei	Document Type DocumentType	10-Q
CY2024Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q3	dei	Document Period End Date DocumentPeriodEndDate	2024-08-31
CY2024Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	dei	Entity File Number EntityFileNumber	333-267039
CY2024Q3	dei	Entity Registrant Name EntityRegistrantName	CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CY2024Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
CY2024Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-4901299
CY2024Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	6201 Bonhomme Road
CY2024Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 435N
CY2024Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2024Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77036
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	598	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	598	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	18743	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	21492	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27537	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35670	usd
CY2024Q3	us-gaap	Assets Assets	46280	usd
CY2024Q2	us-gaap	Assets Assets	57162	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	136302	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	196088	usd
CY2024Q3	us-gaap	Bank Overdrafts BankOverdrafts	1548	usd
CY2024Q2	us-gaap	Bank Overdrafts BankOverdrafts	2408	usd
CY2024Q3	CBIH	Related Party Payables RelatedPartyPayables	572339	usd
CY2024Q2	CBIH	Related Party Payables RelatedPartyPayables	503214	usd
CY2024Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	112629	usd
CY2024Q2	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	151267	usd
CY2024Q3	us-gaap	Loans Payable Current LoansPayableCurrent	7054	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	7054	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22225	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21877	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	852097	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	881908	usd
CY2024Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	249500	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	249361	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4906	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	249500	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	254267	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1101597	usd
CY2024Q2	us-gaap	Liabilities Liabilities	1136175	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10556749347	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10556749347	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10431749347	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10431749347	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4355068	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4255068	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5410385	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5334081	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1055317	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1079013	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46280	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57162	usd
CY2024Q3	us-gaap	Revenues Revenues	178887	usd
CY2023Q3	us-gaap	Revenues Revenues	72821	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	8362	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	8820	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	170525	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	64001	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	61296	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48083	usd
CY2024Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	45873	usd
CY2023Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	95654	usd
CY2024Q3	us-gaap	Professional Fees ProfessionalFees	36570	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	62394	usd
CY2024Q3	us-gaap	Officers Compensation OfficersCompensation	6000	usd
CY2023Q3	us-gaap	Officers Compensation OfficersCompensation	12000	usd
CY2024Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	100000	usd
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	18248	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20953	usd
CY2024Q3	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	142	usd
CY2023Q3	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	1701	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	268129	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	240785	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-97604	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-176784	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23638	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	2339	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	5005	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21299	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5005	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-76305	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-181789	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10458923260	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10458923260	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10331749347	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10331749347	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.000007
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.000007
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00002
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00002
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1079013	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-76305	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1055317	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-591665	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	75000	usd
CY2023Q3	CBIH	Stcok Issued During Period Value Rescission Of Share Sale StcokIssuedDuringPeriodValueRescissionOfShareSale	-19000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-181789	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-717454	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-76305	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-181789	usd
CY2024Q3	CBIH	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	100000	usd
CY2023Q3	CBIH	Issuance Of Common Stock For Services IssuanceOfCommonStockForServices	0	usd
CY2024Q3	CBIH	Amortization Of Right Of Use Asset And Liability AmortizationOfRightOfUseAssetAndLiability	-8133	usd
CY2023Q3	CBIH	Amortization Of Right Of Use Asset And Liability AmortizationOfRightOfUseAssetAndLiability	-23920	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2963	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17444	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-59786	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	58654	usd
CY2024Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2023Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8333	usd
CY2024Q3	CBIH	Change In Bank Overdraft ChangeInBankOverdraft	860	usd
CY2023Q3	CBIH	Change In Bank Overdraft ChangeInBankOverdraft	-0	usd
CY2024Q3	CBIH	Change In Lease Liability ChangeInLeaseLiability	4558	usd
CY2023Q3	CBIH	Change In Lease Liability ChangeInLeaseLiability	-0	usd
CY2024Q3	CBIH	Increase Decrease In Related Party Payables IncreaseDecreaseInRelatedPartyPayables	0	usd
CY2023Q3	CBIH	Increase Decrease In Related Party Payables IncreaseDecreaseInRelatedPartyPayables	50373	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30413	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74620	usd
CY2024Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	usd
CY2023Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	75000	usd
CY2024Q3	CBIH	Rescission Of Shareholder Stock Purchase RescissionOfShareholderStockPurchase	0	usd
CY2023Q3	CBIH	Rescission Of Shareholder Stock Purchase RescissionOfShareholderStockPurchase	-19000	usd
CY2024Q3	CBIH	Change In Lease Liability1 ChangeInLeaseLiability1	-0	usd
CY2023Q3	CBIH	Change In Lease Liability1 ChangeInLeaseLiability1	4435	usd
CY2024Q3	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	-38638	usd
CY2023Q3	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	33481	usd
CY2024Q3	CBIH	Payment Of Sba Loan Current PaymentOfSbaLoanCurrent	-139	usd
CY2023Q3	CBIH	Payment Of Sba Loan Current PaymentOfSbaLoanCurrent	14592	usd
CY2024Q3	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	69126	usd
CY2023Q3	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30627	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70453	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	214	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4167	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	755	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8913	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	969	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4746	usd
CY2024Q3	us-gaap	Interest Paid Net InterestPaidNet	2339	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	5005	usd
CY2024Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q3	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zFdz5GzpUwTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zkZguTT64ZO1">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions. The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. Certain of these estimates could be affected by external conditions, including those unique to the Company’s businesses and general economic conditions. These external conditions could have an effect on the Company’s estimates that could cause actual results to differ materially from its estimates. Actual results could differ from those estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary. Significant estimates relied upon in preparing these statements include revenue recognition, accounts receivable reserves, accrued expenses, share-based compensation and the recoverability of the Company’s net deferred tax assets and any related valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	usd
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-97604	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	30413	usd
CY2024Q3	CBIH	Working Capital WorkingCapital	-833355	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5410385	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	7054	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	7054	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	249500	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	249361	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	256554	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	256415	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	23638	usd
CY2024Q3	CBIH	Debt Instrumen Discount DebtInstrumenDiscount	11000	usd
CY2024Q3	CBIH	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	35017	usd
CY2024Q2	CBIH	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	43150	usd
CY2024Q3	CBIH	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	7480	usd
CY2024Q2	CBIH	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	7480	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27537	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35670	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22225	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21877	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4906	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	22225	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	26873	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	18248	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	20953	usd
CY2024Q3	us-gaap	Revenues Revenues	178887	usd
CY2023Q3	us-gaap	Revenues Revenues	72821	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	8362	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	8820	usd
CY2024Q3	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	20010000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	CBIH	Incorporation Amendment Description IncorporationAmendmentDescription	Company amended its amended and restated articles of incorporation to increase the number of shares designated Series A Preferred Stock from 1,000 to 2,000 and on August 11, 2024, the Board authorized the issuance of the 1,000 shares created by the amendment to a related party.
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10556749347	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10556749347	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10431749347	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10431749347	shares
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5410385	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5410385	usd
CY2024Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3382	usd
CY2020Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3529	usd
CY2021Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3676	usd
CY2022Q3	CBIH	Operating Leases Rent Expense Monthly Payment OperatingLeasesRentExpenseMonthlyPayment	3823	usd
CY2024Q3	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On March 23, 2023, the Company amended the lease to extend its term to June 30, 2024, at a base rent of $4,779 per month. For information regarding the recording of the right-of-use asset and the lease liability in the balance sheets with respect to this lease, see Note 5. This lease was terminated effective May 1, 2024, and on that date, the Company leased premises of approximately 1,367 square feet located at 6201 Bonhomme Road, Suite 435N, Houston, Texas, under a lease dated April 12, 2024. This lease, which has a one-year term that commenced on May 1, 2024, provides for base rent of $1,631 per month.
CY2024Q3	CBIH	Other Liability Noncurrent Related Party1 OtherLiabilityNoncurrentRelatedParty1	572340	usd
CY2023Q3	CBIH	Other Liability Noncurrent Related Party1 OtherLiabilityNoncurrentRelatedParty1	503214	usd
CY2024Q3	us-gaap	Revenues Revenues	178887	usd
CY2023Q3	us-gaap	Revenues Revenues	72821	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-007261-index-headers.html	Edgar Link	pending
0001683168-24-007261-index.html	Edgar Link	pending
0001683168-24-007261.txt	Edgar Link	pending
0001683168-24-007261-xbrl.zip	Edgar Link	pending
cannabisbio_ex3100.htm	Edgar Link	pending
cannabisbio_ex3200.htm	Edgar Link	pending
cannabis_i10q-083124.htm	Edgar Link	pending
cbih-20240831.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
cbih-20240831_def.xml	Edgar Link	unprocessable
cbih-20240831_cal.xml	Edgar Link	unprocessable
cbih-20240831_lab.xml	Edgar Link	unprocessable
cbih-20240831_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cannabis_i10q-083124_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CBIH
Cannabis Bioscience International Holdings, Inc. Stock $cbih

2024 Q4 Form 10-Q Financial Statement

#000168316824007261 Filed on October 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CBIH Cannabis Bioscience International Holdings, Inc. Stock $cbih

2024 Q4 Form 10-Q Financial Statement

#000168316824007261 Filed on October 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CBIH
Cannabis Bioscience International Holdings, Inc. Stock $cbih